SPOTLIGHT: FDA rejects Genasense


Already hammered by poor trial data, Genta announced today that the FDA had formally rejected its leukemia therapy Genasense. Genta's stock dropped more than 20 percent to 54 cents a share. Its stock had already been hurt by the news several days ago that the therapy had failed a trial. "We are keenly disappointed by this decision," Raymond Warrell, Genta's chief executive, said in a statement. "We believe that Genasense has amply demonstrated its efficacy and safety in patients with relapsed and refractory CLL in a carefully designed and executed randomized clinical trial." Release | Report

Suggested Articles

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

The reported requirements suggest a company is unlikely to have the data needed to support an EUA before the election in six weeks.  

Blocking tau appears to be just as fruitless as clearing amyloid buildup when it comes to helping Alzheimer’s disease patients.